Eli Lilly hits out against the use of Mounjaro, Zepbound for 'cosmetic weight loss'

Eli Lilly published an open letter that warns against using Mounjaro and Zepbound to lose weight for looks, after the company became aware of certain practices around the two medicines. Both carry the same active ingredient, tirzepatide.

Labels already draw the line the letter restates. Mounjaro is indicated for type 2 diabetes only, and Zepbound is limited to people with obesity as measured by BMI, or overweight plus at least one weight-related condition. What changed is the audience: celebrity accounts of using these drugs, from Elon Musk to Oprah Winfrey, turned a prescription category into something people talk about the way they talk about body image.

That does not mean a letter settles it. A company can say where its medicines belong and still sell into demand it did not build alone, and the pressure people feel about how they look was never going to be answered by a label. The harder question is who decides what counts as cosmetic, when weight sits between health and appearance for most of the people asking.

Read the full story at Fierce Pharma ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.